On Tuesday, Shares of Fifth Third Bancorp (NASDAQ:FITB) gained 1.13% to $21.52.
Fifth Third Bancorp, stated second quarter 2015 net income of $315 million as compared to net income of $361 million in the first quarter of 2015 and $439 million in the second quarter of 2014. After preferred dividends, net income accessible to common shareholders was $292 million, or $0.36 per diluted share, in the second quarter of 2015, contrast with $346 million, or $0.42 per diluted share, in the first quarter of 2015, and $416 million, or $0.49 per diluted share, in the second quarter of 2014.
Fifth Third Bancorp operates as a diversified financial services company in the United States. It operates through four segments: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors.
Shares of Walt Disney Co (NYSE:DIS), declined -0.23% to $119.31, during its last trading session.
The Walt Disney Studios offers an exclusive look at its forthcoming projects from Disney, Pixar, Marvel and Lucasfilm at D23 EXPO 2015, taking place August 14–16 at the Anaheim Convention Center.
The Studio will unveil its animation and live-action film slates via two huge Hall D23 presentations featuring surprise guests and many unforgettable moments. Other not-to-be-missed events comprise a Frozen FANdemonium musical celebration with Kristen Anderson-Lopez and Robert Lopez and the 20th anniversary celebration of Disney•Pixar’s Toy Story with John Lasseter and the original Pixar crew.
The Walt Disney Company, together with its auxiliaries, operates as an entertainment company worldwide. The company operates in five segments: Media Networks, Parks and Resorts, Studio Entertainment, Consumer Products, and Interactive.
Finally, MiMedx Group Inc (NASDAQ:MDXG), ended its last trade with -0.31% loss, and closed at $12.91.
MiMedx Group declared that its latest peer-reviewed scientific study, “Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro,” was electronically published in the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
